A 6-month depot formulation of leuprorelin acetate proves successful in daily practice
ثبت نشده
چکیده
The established agent leuprorelin acetate can be administered in combination with a novel biodegradable polymer matrix (Atrigel delivery system) to reduce testosterone levels in men with advanced hormone-dependent prostate cancer. Since 2007, this new formulation is available as a 6-month depot (Eligard 45 mg). The results of a recent non-interventional study, investigating the efficacy and safety of Eligard 45 mg in urological practice, are now available.
منابع مشابه
Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study
INTRODUCTION The 1-, 3- and 6- month biodegradable polymer matrix depot formulations of leuprorelin acetate (Eligard(®)/Depo-Eligard(®), Astellas Pharma Inc/BV) were shown to reduce testosterone and prostate-specific antigen levels and to be well tolerated in patients with advanced prostate cancer in several clinical trials. This study aimed at evaluating the efficacy, safety and tolerability o...
متن کاملSix-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-m...
متن کاملLeuprorelin acetate in prostate cancer: a European update.
This review provides an update on leuprorelin acetate, the world's most widely prescribed depot luteinising hormone-releasing hormone analogue. Leuprorelin acetate has been in clinical use in the palliative treatment of prostate cancer for more than 20 years, but advances continue to be made in terms of convenience and flexibility of administration, and in the incorporation of leuprorelin aceta...
متن کاملEfficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
BACKGROUND Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, is used worldwide in premenopausal women with hormone receptor-positive breast cancer. This study was conducted to assess the non-inferiority of the 6-month depot formulation, TAP-144-SR (6M) 22.5 mg to the 3-month depot formulation, TAP-144-SR (3M) 11.25 mg in postoperative, premenopausal patients with hormone rec...
متن کاملDepot leuprorelin acetate-induced granulomas manifested as persistent suppurative nodules.
) is a synthetic agonist analogue of gonadotrophin-releasing hormone (Gn-RH or luteinizing hormone-releasing hormone), administered as intramuscular or subcutaneous injections, and indicated for the treatment of advanced prostate cancer. In the last decade, sustained release parenteral depot formulations have been developed, by entrapping the hydrophilic leuprorelin in biodegradable highly lip...
متن کامل